

# Eugene K Cha

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6610050/eugene-k-cha-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84  
papers

4,199  
citations

37  
h-index

64  
g-index

93  
ext. papers

5,023  
ext. citations

5.8  
avg, IF

4.63  
L-index

#	Paper	IF	Citations
84	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101485	2.2	2
83	Association of patientsTsex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3337-3344	4	3
82	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1214-1221	8.7	4
81	Reply by Authors. <i>Journal of Urology</i> , <b>2020</b> , 204, 684	2.5	
80	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. <i>Journal of Urology</i> , <b>2020</b> , 204, 460-465	2.5	2
79	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. <i>Journal of Urology</i> , <b>2020</b> , 204, 677-684	2.5	9
78	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. <i>Journal of Pathology</i> , <b>2019</b> , 248, 260-265	9.4	20
77	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 967-976	12.9	94
76	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2019</b> , 5, 201-204	5.1	18
75	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. <i>European Urology Focus</i> , <b>2019</b> , 5, 104-108	5.1	36
74	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , <b>2019</b> , 5, 365-368	5.1	9
73	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. <i>BJU International</i> , <b>2018</b> , 122, 627-632	5.6	14
72	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , <b>2018</b> , 36, 645-653	4	2
71	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1965-1973	12.9	51
70	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	15
69	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. <i>Urology</i> , <b>2018</b> , 122, 121-126	1.6	5
68	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3610-3618	12.9	143

67	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. <i>Journal of Urology</i> , <b>2017</b> , 198, 546-551	2.5	3
66	Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 151.e9-151.e15	2.8	8
65	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , <b>2017</b> , 72, 952-959	10.2	168
64	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , ,	3.3	7
63	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	14
62	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 484.e19-484.e25	2.8	39
61	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , <b>2016</b> , 2, 165-202 <sup>1</sup>		22
60	Impact of Uteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. <i>Urology</i> , <b>2016</b> , 94, 148-53	1.6	22
59	Low yield of surveillance imaging after surgery for T1 kidney cancer. <i>World Journal of Urology</i> , <b>2016</b> , 34, 949-53	4	2
58	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , <b>2016</b> , 17, 9	2.9	22
57	Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. <i>Current Urology Reports</i> , <b>2016</b> , 17, 12	2.9	23
56	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , <b>2016</b> , 48, 356-8	36.3	111
55	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , <b>2016</b> , 195, 1684-1689	2.5	27
54	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , <b>2016</b> , 122, 3715-3723	6.4	37
53	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. <i>BJU International</i> , <b>2016</b> , 118, 44-52	5.6	72
52	Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?. <i>Urologic Clinics of North America</i> , <b>2015</b> , 42, 189-99, viii	2.9	7
51	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , <b>2015</b> , 68, 970-7	10.2	147
50	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , <b>2015</b> , 67, 74-82	10.2	149

49	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. <i>European Urology</i> , <b>2015</b> , 67, 198-201	10.2	105
48	Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. <i>European Urology</i> , <b>2015</b> , 67, 350-1	10.2	2
47	Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 217-25	2.8	21
46	Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. <i>Journal of Urology</i> , <b>2014</b> , 191, 830-41	2.5	15
45	Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Urology</i> , <b>2014</b> , 65, 210-7	10.2	150
44	Risk factors for the development of parastomal hernia after radical cystectomy. <i>Journal of Urology</i> , <b>2014</b> , 191, 1708-13	2.5	55
43	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 47.e9-14	2.8	44
42	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , <b>2013</b> , 111, 249-55	5.6	61
41	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , <b>2013</b> , 111, 74-84	5.6	24
40	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. <i>BJU International</i> , <b>2013</b> , 111, 404-11	5.6	35
39	Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. <i>World Journal of Urology</i> , <b>2013</b> , 31, 817-22	4	28
38	Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. <i>European Urology</i> , <b>2013</b> , 63, 371-8	10.2	39
37	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , <b>2013</b> , 111, E30-6	5.6	60
36	Cost-effective treatment of low-risk carcinoma not invading bladder muscle. <i>BJU International</i> , <b>2013</b> , 111, E78-84	5.6	17
35	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , <b>2013</b> , 31, 5-11	4	27
34	Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. <i>European Urology</i> , <b>2013</b> , 63, 1082-90	10.2	65
33	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1716-24	2.8	13
32	Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. <i>European Urology</i> , <b>2013</b> , 64, 837-45	10.2	47

31	Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 531-40	5	42
30	Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. <i>European Urology</i> , <b>2012</b> , 61, 185-92	10.2	32
29	The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. <i>European Urology</i> , <b>2012</b> , 61, 245-53	10.2	135
28	Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. <i>European Urology</i> , <b>2012</b> , 61, 237-42	10.2	54
27	Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. <i>European Urology</i> , <b>2012</b> , 61, 854-5	10.2	138
26	Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Urology</i> , <b>2012</b> , 61, 818-25	10.2	153
25	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , <b>2012</b> , 109, 685-90	5.6	23
24	Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. <i>BJU International</i> , <b>2012</b> , 109, 613-614	5.6	
23	Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). <i>BJU International</i> , <b>2012</b> , 109, 968-85	5.6	21
22	Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. <i>BJU International</i> , <b>2012</b> , 110, 63-8	5.6	13
21	International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. <i>BJU International</i> , <b>2012</b> , 110, 674-81	5.6	16
20	Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. <i>BJU International</i> , <b>2012</b> , 110, 1463-70	5.6	32
19	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , <b>2012</b> , 30, 753-9	4	23
18	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. <i>World Journal of Urology</i> , <b>2012</b> , 30, 847-52	4	18
17	Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. <i>European Urology</i> , <b>2012</b> , 62, 677-84	10.2	74
16	Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. <i>Journal of Urology</i> , <b>2012</b> , 187, 457-62	2.5	38
15	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. <i>Journal of Urology</i> , <b>2012</b> , 187, 845-51	2.5	42
14	Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 4337-44	3.1	42

13	Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. <i>Journal of Urology</i> , <b>2012</b> , 188, 398-404	2.5	78
12	Biomolecular predictors of urothelial cancer behavior and treatment outcomes. <i>Current Urology Reports</i> , <b>2012</b> , 13, 122-35	2.9	45
11	Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 1826-32	8.7	23
10	Recent advances in robot-assisted radical cystectomy. <i>Current Opinion in Urology</i> , <b>2011</b> , 21, 65-70	2.8	14
9	Current status of robotic partial nephrectomy (RPN). <i>BJU International</i> , <b>2011</b> , 108, 935-41	5.6	37
8	Immunohistochemical biomarkers for bladder cancer prognosis. <i>International Journal of Urology</i> , <b>2011</b> , 18, 616-29	2.3	42
7	Stage pT0 after radical cystectomy: are all patients equal?. <i>European Urology</i> , <b>2011</b> , 60, 603-4	10.2	1
6	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. <i>World Journal of Urology</i> , <b>2011</b> , 29, 473-80	4	41
5	Impact of gender on bladder cancer incidence, staging, and prognosis. <i>World Journal of Urology</i> , <b>2011</b> , 29, 457-63	4	154
4	Prognostic factors for upper urinary tract urothelial carcinoma. <i>Nature Reviews Urology</i> , <b>2011</b> , 8, 440-7	5.5	81
3	Tim-2 regulates T helper type 2 responses and autoimmunity. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 437-44	16.6	104
2	Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. <i>Nature Immunology</i> , <b>2003</b> , 4, 1102-10	19.1	486
1	Role of extended lymphadenectomy 176-183		